1. |
Nyholm D. Duodopa® treatment for advanced Parkinson's disease:a review of efficacy and safety. Parkinsonism Relat Disord, 2012, 18(8):916-929.
|
2. |
Chen JJ, Swope DM. Clinical pharmacology of rasagiline:a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol, 2005, 45(8):878-894.
|
3. |
Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter:diagnosis and prognosis of new onset Parkinson disease(an evidencebased review):report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2006, 66(7):968-975.
|
4. |
邓可刚.循证医学证据的检索步骤与检索系统的选择.中国循证医学杂志, 2004, 4(9):634-637.
|
5. |
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. Available at: http://www.cochranehandbook.org.[2013-03-20].
|
6. |
刘鸣.临床研究选择和纳入.刘鸣, 主编.系统评价、Meta-分析设计与实施方法.第1版.北京:人民卫生出版社, 2011:97-108.
|
7. |
陈耀龙, 李幼平, 杜亮, 等.医学研究中证据分级和推荐强度的演进.中国循证医学杂志, 2008, 8(2):127-133.
|
8. |
袁金秋, 刘雅莉, 杨克虎, 等.系统评价在评价纳入研究的质量评价方法调查.中国循证医学杂志, 2012, 12(2):238-242.
|
9. |
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations:the PRESTO study. Arch Neurol, 2005, 62(2):241-248.
|
10. |
Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations(LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily study):a randomised, double-blind, parallel-group trial. Lancet, 2005, 365(1):947-954.
|
11. |
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease:the TEMPO Study. Arch Neurol, 2002, 59(1):1937-1943.
|
12. |
Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord, 2004, 19(8):916-923.
|
13. |
Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayedstart trial of rasagiline in Parkinson's disease. N Engl J Med, 2009, 361(13):1268-1278.
|
14. |
Rabey JM, Sagi I, Huberman M, et al. Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease:A Double-Blind Study as Adjunctive Therapy to Levodopa. Clin Neuropharmacol, 2000, 23(6):324-330.
|
15. |
Kathryn DG, Vanessa KH. Adjunctive therapy in Parkinson's disease:the role of rasagiline. Neuropsychiatr Dis Treat, 2012, 9(1):285-294.
|
16. |
Bar-Am O, Weinreb O, Amit T, et al. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem, 2010, 112(5):1131-1137.
|
17. |
Swarztrauber K, Koudelka C, Brodsky MA. Initial pharmacotherapy in population of veterans with parkinson diesase. Neurology, 2006, 66(9):1425-1426.
|
18. |
Keating GM, Lyseng-Williamson KA, Hoy SM. Rasagiline:a guide to its use in Parkinson's disease. CNS Drugs, 2012, 26(9):781-785.
|
19. |
Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effect of Selegiline on mortality in partients with Parkinson's disease:a meta-analysis. Neurology, 1998, 51(3):825-830.
|
20. |
Przuntek H, Conrad B, Dichgans J, et al. SELEDO:a 5-year longterm trial on the effect of Selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol, 1999, 6(2):141-150.
|
21. |
The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol, 1996, 40(1):99-107.
|